EuroBiotech: More Articles of Note


> F-star named Darlene Deptula-Hicks as CFO. The appointment of a U.S.-based financial chief with experience at publicly traded biotechs comes as F-star increases its focus on internal assets. Release 

> BioNTech and Genmab began a first-in-human trial of a PD-L1x4-1BB bispecific in solid tumors. Statement  

> CyTuVax posted data from a phase 2 trial of hepatitis B vaccine HBAI20. The Dutch biotech thinks HBAI20 may work in non-responders to existing vaccines. Release  


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

> Oncopeptides presented phase 2 data on melflufen in multiple myeloma. Analysts at Jefferies said the response rate underscored the potential of the peptide-conjugated alkylator. Release  

> Oryzon posted dose-finding results from a phase 2 trial of Iadademstat in acute myeloid leukemia. Four-fifths of participants responded to the drug. Statement  

> Medigene shared an updated interim analysis of its acute myeloid leukemia trial. Two of the five early relapses showed mutational load upon entering the study. Release 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.